References
- Scheller D, Ullmer C, Berkels R, et al. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease. Naunyn Schmiedebergs Arch Pharmacol 2009;379:73-86
- European Medicines Agency. Neupro: EPAR – Product Information. 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000626/WC500026397.pdf [Last accessed April 2013]
- US Prescribing Information. Neupro. 2012. Available at: http://www.ucb.com/_up/ucb_com_products/documents/Neupro%20COL%2004-2012.pdf [Last accessed April 2013]
- Chaudhuri KR. Crystallisation within transdermal rotigotine patch: is there cause for concern? Expert Opin Drug Deliv 2008;5:1169-71
- Braun M, Cawello W, Boekens H, et al. Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine. Br J Clin Pharmacol 2009;67:209-15
- Cawello W, Braun M, Boekens H. Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery. Drug Metab Dispos 2009;37:2055-60
- Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: Skin irritation and sensitization testing of generic transdermal drug products. 1999. Available at: http://www.fda.gov/ohrms/dockets/98fr/990236Gd.pdf [Last accessed April 2013]
- Lehmann EL, D’Abrera HJM. Nonparametrics: Statistical methods based on ranks. New York: Springer, 2006
- Malik M, Andreas JO, Hnatkova K, et al. Thorough QT/QTc study in patients with advanced Parkinson’s disease: cardiac safety of rotigotine. Clin Pharmacol Ther 2008;84:595-603
- Elshoff JP, Braun M, Andreas JO, et al. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther 2012;34:966-78
- Whitesides J, Cawello W, Woltering F, et al. Stable plasma levels of rotigotine following transdermal patch removal and new patch application during long-term treatment of patients with advanced Parkinson’s disease. Mov Disord 2011;26(S2):S288
- Whitesides J, Cawello W, Braun M, et al. Stability of rotigotine plasma levels during long-term transdermal application for patients with idiopathic restless legs syndrome. Mov Disord 2011;26(S2):S365 [Abstract]
- European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on the investigation of bioequivalence. 2010. Available at: http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf [Last accessed April 2013]
- Davis KL, Edin HM, Allen JK. Prevalence and cost of medication nonadherence in Parkinson’s disease: evidence from administrative claims data. Mov Disord 2010;25:474-80
- Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson’s disease. Mov Disord 2005;20:1502-7
- Grosset KA, Reid JL, Grosset DG. Medicine-taking behavior: implications of suboptimal compliance in Parkinson’s disease. Mov Disord 2005;20:1397-404
- Leopold NA, Polansky M, Hurka MR. Drug adherence in Parkinson’s disease. Mov Disord 2004;19:513-17
- Grosset D. Therapy adherence issues in Parkinson’s disease. J Neurol Sci 2010;289:115-18
- Grosset D, Grosset K, Emmerman A, et al. Improved selfreported compliance with transdermal (patch) versus oral medication in Parkinson’s disease patients. Eur J Neurol 2006;13(Suppl 2):P1175 [abstract]
- Schnitzler A, Leffers KW, Hack HJ. High compliance with rotigotine transdermal patch in the treatment of idiopathic Parkinson’s disease. Parkinsonism Relat Disord 2010;16:513-16